UPDATE: Teva Pharma (TEVA) Misses Q3 EPS by 4c, Q4 Guidance Comes in Light
Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.00, $0.04 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $5.61 billion versus the consensus estimate of $5.62 billion.
Updated 2017 Financial Outlook" style="margin: 0px 0px 1em; color: rgb(38, 40, 42); ">Updated 2017 Financial Outlook
FY 2017 | Implied Q4 2017 Outlook | |||
| Revenues | $22.2-22.3 billion (previously $22.8-23.2 billion) | $5.3-5.4 billion | ||
| Non-GAAP EPS | $3.77-3.87 (previously $4.30-4.50) | $0.70-0.80 | ||
| Cash flow from operations | $3.15-3.3 billion (previously $4.4-4.6 billion) | $0.85-1.0 billion |
(Street sees Q4 EPS of $1.01 on revenue of $5.58 billion)
For earnings history and earnings-related data on Teva Pharma (TEVA) click here.